Hepatotoxicity with thiazolidinediones: Is it a class effect?

Drug Safety

Volumn 24, Issue 12, 2001, Pages 873-888

  Scheen, A J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALANINE AMINOTRANSFERASE; CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450 3A4; ETHINYLESTRADIOL; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; GLUCOSE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LISINOPRIL; LIVER ENZYME; METFORMIN; NIFEDIPINE; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PIOGLITAZONE; PREDNISONE; QUINONE DERIVATIVE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TACROLIMUS; TROGLITAZONE; UNCLASSIFIED DRUG; WARFARIN; ZAFIRLUKAST;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIET THERAPY; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; ENZYME INDUCTION; FATTY LIVER; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER FAILURE; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATIENT SELECTION; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0035169430     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200124120-00002     Document Type: Review

References (138)

1. Pathophysiology of type 2 diabetes
2. Insulin resistance and atherosclerosis
3. Management of the obese diabetic patient
4. Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s: Achievements and future developments
5. Drug administration in patients with diabetes mellitus. Safety considerations
6. Thiazolidinediones in the treatment of insulin resistance type II diabetes
7. Mechanisms and clinical effects of thiazolidinediones
8. Thiazolidinediones
9. Thiazolidinediones: A new class of antidiabetic drugs
10. Les thiazolidinediones
11. Thiazolidinediones: An update
12. Insulin resistance and antidiabetic drugs
13. Oral antidiabetic agents: A guide to selection
14. Antidiabetic drugs present and future: Will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus?
15. PPAR-g adipogenic regulator and thiazolidinedione receptor
16. Troglitazone
17. Troglitazone: An antidiabetic agent
18. Troglitazone: Review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus
19. Troglitazone. A review of its use in the management of type 2 diabetes mellitus
20. Hepatic dysfunction associated with troglitazone
21. Hepatotoxicity due to troglitazone: Report of two cases and review of adverse events reported to the United States Food and Drug Administration
22. Rosiglitazone
23. Pioglitazone
24. Rosiglitazone and pioglitazone: Two new thiazolidinediones
25. Not all glitazone tarnished by hepatotoxicity
26. Are all glitazones the same? Satellite symposium of the EASD 1999
27. The glitazones: Proceed with caution
28. Thiazolidinedione hepatotoxicity: A class effect?
29. Liver disease and diabetes mellitus
30. Nonalcoholic steatohepatitis
31. Review: Non alcoholic steatohepatitis
32. Non-alcoholic steatohepatitis (NASH): A disease of emerging identity importance
33. Nonalcoholic steatohepatitis
34. Non-alcoholic steatohepatitis: Association with obesity and insulin resistance, and influence of weight loss
35. Liver diseases and diabetes mellitus
36. Diabetes mellitus and the liver
37. Liver function tests in diabetic patients
38. Prevalence of abnormal serum alanine aminotransferase levels in obese patients and patients with type 2 diabetes
39. Liver disturbances in obesity and diabetes mellitus
40. Studies of the liver in diabetes mellitus II. The significance of fatty metamorphosis and its correlation with insulin insensitivity
41. The pathology of diabetic hepatitis
42. Fatty liver steatosis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors
43. Liver pathology in morbidly obese patients with and without diabetes
44. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity
45. Association of diabetes mellitus and chronic hepatitis C infection
46. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States
47. Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents
48. Drug-induced hepatic disorders: Incidence, management and avoidance
49. Drug-induced hepatotoxicity
50. Criteria of drug-induced liver disorders: Report of an international consensus meeting
51. Causal or casual? The role of causality assessment in pharmacovigilance
52. Update: Clinically significant cytochrome P 450 drug intercations
53. In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: Comparison with pioglitazone and rosiglitazone
54. Troglitazone: Antihyperglycemic activity and potential role in the treatment of type 2 diabetes
55. Diabetes drug withdrawn after reports of hepatic events
56. Troglitazone. Is it all over?
57. The rise and fall of troglitazone
58. Liver damage warnings for troglitazone
59. Call to ban troglitazone in US
60. Troglitazone ban loses support
61. Two cases of severe clinical histologic hepatotoxicity associated with troglitazone
62. Troglitazone-induced hepatic failure leading to liver transplantation
63. An autopsy case of troglitazone-induced fulminant hepatitis
64. Fatal hepatotoxicity associated with troglitazone
65. Troglitazone-associated hepatic failure
66. Severe hepatotoxicity associated with troglitazone
67. Troglitazone-associated hepatic failure
68. A Japanese case of liver dysfunction after 19 months of troglitazone treatment
69. Rapid-onset subfulminant liver failure associated with troglitazone
70. Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: A case report with autopsy examination
71. Hepatic injury due to troglitazone
72. Troglitazone-induced fulminant hepatic failure
73. Severe but reversible hepatitis induced by troglitazone
74. Troglitazone-associated hepatic failure
75. Troglitazone-associated hepatotoxicity treated successfully with steroids
76. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes
77. Liver dysfunction associated with troglitazone (Noscal)
78. Liver dysfunction due to troglitazone
79. Clinical effect and side effect of troglitazone
80. Learning to use troglitazone
81. A novel antidiabetic drug, troglitazone - Reason for hope and concern
82. Liver enzyme monitoring in patient treated with troglitazone
83. Hepatic injury due to drugs and toxins
84. Meta-analysis of steady-state pharmacokinetics of troglitazone and its metabolites
85. Clinical pharmacokinetics of troglitazone
86. Pharmacokinetics of troglitazone, a PPAR-gamma agonist, in patients with hepatic insufficiency
87. Co-administration of acetaminophen and troglitazone: Pharmacokinetics and safety
88. Pharmacokinetics of troglitazone, an antidiabetic agent: Prediction of in vivo stereo-selective sulphation and glucuronidation from in vitro data
89. Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs
90. Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes
91. Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes
92. Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes
93. Factors associated with the risk of liver enzyme elevation in patients with type 2 diabetes treated with a thiazolidinedione
94. Drug-induced liver injury: Mechanisms and test systems
95. Troglitazone has a scavenging effect on reactive oxygen species
96. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission
97. Use of hepatocyte cultures for the study of hepatotoxicity compounds
98. The role of conjugation in hepatotoxicity of troglitazone in human and porcine hepatocyte cultures
99. Toxicity of troglitazone in cultured rat hepatocytes
100. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: In vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat
101. The role of hepatic peroxisome proliferator-activated receptors (PPARs) in health and disease
102. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrinogenic and proinflammatory actions in hepatic stellate cells
103. Troglitazone prevents fatty changes of the liver in obese diabetic rats
104. Thiazolidinediones and liver toxicity
105. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis
106. Lessons from the glitazones: A story of drug development
107. Rosiglitazone
108. Rosiglitazone in the treatment of type 2 diabetes mellitus: A critical review
109. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: A twelve-week randomized, placebo controlled study
110. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes
111. Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus
112. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients
113. Effect of metformin rosiglitazone combination therapy in patients with type 2 diabetes mellitus
114. Rosiglitazone is not associated with hepatotoxicity
115. Rosiglitazone liver safety update
116. Rapid reversal of hepatic steatosis by rosiglitazone
117. Hepatic failure in a patient taking rosiglitazone
118. Hepatocellular injury in a patient receiving rosiglitazone: A case report
119. Rosiglitazone and hepatic failure
120. Rosiglitazone and liver failure
121. Rosiglitazone toxicity
122. Canada reports 166 ADRs with Avandia
123. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizerin humans
124. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone
125. Rosiglitazone does not markedly alter CYP3A4-mediated drug metabolism
126. Arzneimittelinteraktionen - Ihre bedeutung für eine sichere therapie am beispiel der neuen wirkstoffgruppe der thiazolidindione (Glitazone)
127. Effect of hepatic impairment on the pharmacokinetics of rosiglitazone
128. New drug overview. Pioglitazone hydrochloride
129. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes
130. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled study
131. Pioglitazone liver enzyme profile is similar to placebo in U.S. controlled clinical trials
132. Safety and tolerability of pioglitazone
133. y mice
134. Clinical pharmacokinetics of pioglitazone
135. Thiazolidinediones for type 2 diabetes. No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4
136. In vitro studies on the metabolic pathways of pioglitazone
137. Pioglitazone has low potential for drug interactions